Number of the records: 1

sorafenib

Topical term	sorafenib
See link	4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate (UF)
	BAY 43-9006 (UF)
	BAY 545-9085 (UF)
	BAY-545-9085 (UF)
	BAY-673472 (UF)
	Nexavar (UF)
	pyridin-N-oxid (UF)
	Sorafenib N-Oxide (UF)
	sorafenib tosylát (UF)
	Sorafenib Tosylate (UF)
See also	fenylmočovinové sloučeniny
	niacinamid
	antitumorózní látky (PA)
	inhibitory proteinkinas (PA)
Linking entry	Sorafenib
Conspect	D02. - 065. - 950. - 681. - 757
	D02. - 455. - 426. - 559. - 389. - 703. - 757
	D03. - 066. - 515. - 530. - 750
	D03. - 383. - 725. - 547. - 530. - 750
Note	A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Database	MESH
References	(2) - MESH

subject heading

Number of the records: 1